Early signs of mild to moderate dehydration include: Thirst and dry mouth (though thirst may be blunted in some individuals, particularly older adults) Dark yellow or amber-coloured urine with reduced frequency of urination Fatigue, dizziness, or light-headedness , particularly upon standing (orthostatic symptoms) Headache and difficulty concentrating Dry skin with reduced elasticity (skin turgor test: pinched skin returns slowly to normal) Constipation or worsening of existing constipation More severe dehydration may present with: Rapid heartbeat and breathing Sunken eyes and pronounced facial hollowing Confusion or irritability Very dark urine or absence of urination for more than 8 hours Severe dizziness or fainting Patients should contact their GP or NHS 111 promptly if they experience: Persistent vomiting or diarrhoea lasting more than 24 hours despite oral rehydration attempts Inability to keep down fluids for more than 12 hours Signs of moderate dehydration that do not improve with increased oral fluid intake Symptoms of acute kidney injury (reduced urine output, swelling, confusion) Immediate medical attention (A&E or 999) is warranted if: Severe dehydration symptoms are present (confusion, rapid heart rate, fainting) There is suspected acute pancreatitis (severe, persistent abdominal pain radiating to the back, often accompanied by vomiting) in this case, stop taking tirzepatide immediately and do not restart unless pancreatitis has been excluded [1] [2] Signs of diabetic ketoacidosis occur in patients with diabetes (excessive thirst, frequent urination, fruity breath odour, confusion) The Mounjaro SmPC specifically highlights the importance of monitoring for dehydration-related complications, particularly acute kidney injury, which has been reported predominantly in patients experiencing severe gastrointestinal adverse reactions
Group 5: Rats received MD (200 mg/kg/day, i.p.) for 5 days prior to and 5 days following a single MTX dose (20 mg/kg, i.p)
GLP-1s have proven effective at helping people lose weight and get their blood sugar under control, potentially reducing the risk of heart attacks, strokes and other serious health conditions
Tanovea is associated with dermatopathies which can worsen with subsequent treatment
For people not on anticoagulants, the thrombosis research suggests BPC-157 may support healthy blood fluidity without tipping into excessive bleeding risk
